Zuclopenthixol acetate: no clear benefit over standard drugs, and sedation lasts longer

Design

Cochrane systematic review and meta-analysis of 11 randomised trials

Population

714 people with acute schizophrenia or similar illness and acute behavioural disturbance

Primary outcome

Tranquillisation and sedation from 15 minutes to 48 hours, global state and adverse effects

Effect

Tranquillisation at 15 minutes RR 2.27 (95% CI 0.89 to 5.81); sedation at 24 hours RR 0.25 (0.11 to 0.54)

This Cochrane update included 11 randomised trials (714 participants) of intramuscular zuclopenthixol acetate for acute behavioural disturbance in schizophrenia and similar illness, compared with standard drugs. Certainty ranged from moderate to very low, and 10 of 11 trials showed selective reporting.

Tranquillisation at 15 minutes did not differ from haloperidol plus promethazine (RR 2.27, 95% CI 0.89 to 5.81; one study, 74 participants; low certainty). More people were sedated with haloperidol plus promethazine at 15 minutes (RR 1.31, 95% CI 1.06 to 1.63), but more were sedated with zuclopenthixol acetate at 24 hours (RR 0.25, 95% CI 0.11 to 0.54) and 48 hours (RR 0.62, 95% CI 0.43 to 0.89), all moderate certainty from one study. Adverse effects did not differ (low certainty). Less additional benzodiazepine was needed, but that was very uncertain.

The authors caution against recommendations that favour zuclopenthixol acetate over standard drugs. Its prolonged sedation is a reason to plan observation and avoid it where fast recovery matters.

• Do not choose zuclopenthixol acetate expecting faster tranquillisation; the evidence shows no clear advantage at 15 minutes.
• If used, plan for sedation lasting 24 to 48 hours and monitor accordingly.
• Prefer the agent your team knows best when evidence does not separate options.
• Doses of 25 to 50 mg may match 50 to 100 mg, but this rests on one small study of 30 people.
• Check the local formulary and protocol; this review has not changed any guideline.

Why it matters

Its appeal is a long-acting depot-like effect, and the review finds that effect shows up as prolonged sedation, not better control.

Don't overread it

Mostly single small trials with selective reporting; the review does not rule out a benefit for specific patients.

The statistics, in plain English

Most of these comparisons rest on a single small trial, so the confidence intervals are wide and the findings fragile. Moderate certainty here still means a single study of 74 people. A significant sedation difference at 24 hours tells you about duration, not about better control of agitation.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.